openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
Warnings sections page 1 of 1 · 1 matching rows.
warnings
WARNINGS Use of sympathomimetic amines with monoamine oxidase inhibitors or tricyclic antidepressants may result in potentiation of the pressor effect. (See PRECAUTIONS, Drug Interactions.) Metaraminol bitartrate injection contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people.
ADVERSE REACTIONS Sympathomimetic amines, including metaraminol bitartrate injection, may cause sinus or ventricular tachycardia, or other arrhythmias, especially in patients with myocardial infarction. (See PRECAUTIONS.) In patients with a history of malaria, these compounds may provoke a relapse. Abscess formation, tissue necrosis, or sloughing rarely may follow the use of metaraminol bitartrate injection. In choosing the site of injection, it is important to avoid those areas recognized as not suitable for use of any pressor agent and to discontinue the infusion immediately if infiltration or thrombosis occurs. Although the physician may be forced by the urgent nature of the patient's condition to choose injection sites that are not recognized as suitable, he should, when possible, use the preferred areas of injection. The larger veins of the antecubital fossa or the thigh are preferred to veins in the dorsum of the hand or ankle veins, particularly in patients with peripheral vascular disease, diabetes mellitus, Buerger's disease, or conditions with coexistent hypercoagulability.